Bioniche Hosts Veterinarians and Food Industry Reps at Two-Day E. coli O157:H7 Vaccine Conference

    - guest speakers included a World Health Organization expert on E. coli -

    BELLEVILLE, ON, June 27 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC), a
research-based, technology-driven Canadian biopharmaceutical company, hosted a
two-day conference in Toronto this week entitled, "E. coli O157 Vaccine: Added
Value or Added Cost". The audience included veterinarians and representatives
from the food industry: Beef, dairy, and other agricultural commodity
    Guest speakers included Dr. David Biesenthal, a veterinarian in
Walkerton, Ontario whose cattle farm was one of those implicated in the town's
water contamination with E. coli O157:H7 in 2000. Dr. Biesenthal is one of the
first adopters of a vaccination program using the Bioniche E. coli O157:H7
cattle vaccine. "Vaccination of all cattle could help reduce the opportunity
for another incident like the one that occurred in Walkerton and would
demonstrate due diligence," he said.
    Kevin Grier, Senior Market Analyst with the George Morris Centre in
Guelph, Ontario presented data from an economic cost-benefit analysis
completed for Bioniche related to the vaccine. The analysis concluded that
there is a potential $2 saved for every $1 spent on vaccination of the
Canadian cattle herd. An executive summary of the report is available on the
    Dr. John Fairbrother, Director of the Reference Laboratory for
Escherichia coli (E. coli) at the University of Montreal discussed a variety
of potential intervention strategies to address on-farm contamination with E.
coli. He concluded that an optimal strategy is a global approach, using
combined intervention strategies to improve food safety. Dr. Fairbrother was
named as World Health Organization expert on E. coli in 2006.
    Dr. David Smith, Professor and Extension Dairy/Beef Veterinarian in the
Department of Veterinary and Biomedical Sciences at the University of
Nebraska-Lincoln summarized the results of field studies with the Bioniche
vaccine at university feedlots over the last six years. He noted that the
Bioniche vaccine fulfils the expectations of an efficacious vaccine.
    Another guest speaker was Dr. Guy Loneragan, Associate Professor,
Agriculture Sciences and Epidemiologist in the Feedlot Research Group at West
Texas A&M University. Dr. Loneragan discussed his analysis of the applied
interventions against E. coli O157:H7 in real-world studies, as well as
peer-reviewed publications. In response to the question, "How much
intervention is enough?", Dr. Loneragan said, "If we knew the pathogen
threshold level in meat processing plants - the acceptable level that meat
processing and packing facilities can handle with internal interventions - we
could easily assess the efficacy required of a pre-harvest intervention.
Unfortunately, this threshold is yet to be well-defined. That said, however,
the vaccine intervention appears to change summertime shedding patterns into
winter-type patterns. Empirical data from human health tells us this change is
important. I believe that vaccine technology probably has the broadest
application and is the most widely implementable."
    Dr. Doug Powell, Associate Professor in the Department of Diagnostic
Medicine/Pathobiology at Kansas State University, discussed the need to create
a food safety culture, from farm-to-fork, 24/7. He emphasized that risk
reduction strategies are key to ensuring food safety. "The Bioniche vaccine is
a technology to reduce risk. Any tool you can provide for risk reduction will
    "We are pleased with the level of interest in our vaccine on the part of
veterinarians, researchers and the food industry," said Rick Culbert,
President of Bioniche Food Safety. "We are in an awareness building phase,
whereby we are introducing various segments of the food industry to both our
vaccine and the impact of E. coli O157:H7 on human health."
    Bioniche has developed the world's first cattle vaccine that may be used
as an on-farm intervention to reduce the amount of E. coli O157:H7 shed by
cattle. This will be the first product manufactured in the scaled-up
production facility being developed in Belleville, Ontario. The vaccine is
unique in that it helps to reduce shedding of an organism that, while
potentially lethal to humans, causes no disease in cattle. The Company
obtained approval to distribute its vaccine under the Permit to Release
Veterinary Biologics regulations by the Canadian Food Inspection Agency (CFIA)
in December, 2006. In February of this year, the United States Department of
Agriculture (USDA) granted eligibility for conditional licensing of the
    It remains very clear that there is a pressing need to reduce the amount
of E. coli O157:H7 shed into the environment by cattle. Food recalls continue
to occur on a regular basis in beef, produce and prepared food. On-farm
interventions to reduce the shedding of E. coli O157:H7 by cattle, such as
vaccination, may assist in reducing the potential for food and water
contamination and the resulting human illnesses and deaths.
    Approximately 100,000 cases of human infection with the E. coli O157:H7
organism are reported each year in North America. 2% to 7% of those people
develop hemolytic uremic syndrome (HUS), a disease characterized by kidney
failure (in recent outbreaks, this percentage has risen to as high as 16%).
Five percent of HUS patients die, many of them children and senior citizens,
whose kidneys are more sensitive to damage.
    Beyond consumption of contaminated food or water, individuals can become
infected from E. coli O157:H7 by visiting animal exhibits. Petting zoos,
fairs, and agricultural exhibits provide many possible routes of transmission
for E. coli. Direct animal contact is the obvious route, but contact with
contaminated products (e.g., sawdust, shavings, soiled clothing or shoes) can
also lead to human infection.

    About the E. coli O157:H7 Cattle Vaccine

    This vaccine received international recognition in September, 2007 by the
Animal Pharm Industry Excellence Awards as the best new veterinary product for
livestock globally. The vaccine has been developed by a strategic alliance
formed in 2000 between the University of British Columbia (UBC), the Alberta
Research Council (ARC), the University of Saskatchewan's Vaccine & Infectious
Disease Organization (VIDO), and Bioniche, which holds the rights for
worldwide commercialization of the vaccine. The vaccine prevents the E. coli
O157:H7 bacteria from attaching to the intestines of vaccinated cattle,
thereby reducing their reproduction within the animal, and reducing the amount
of bacteria that can be released through cattle manure in the environment.
More than 30,000 cattle have been involved in clinical testing of the vaccine
over the past five years.

    About Bioniche Life Sciences Inc.

    Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery, development,
manufacturing, and marketing of proprietary products for human and animal
health markets worldwide. The fully-integrated company employs approximately
200 skilled personnel and has three operating divisions: Human Health, Animal
Health, and Food Safety. The Company's primary goal is to develop proprietary
cancer therapies supported by revenues from marketed products in human and
animal health. Bioniche has been named one of Canada's Top Ten Life Sciences
Companies for 2008. For more information, please visit

    Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause, but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process, and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

    %SEDAR: 00013159EF

For further information:

For further information: Jennifer Shea, Corporate Communications,
Investor & Government Relations Director, Bioniche Life Sciences Inc.,
Telephone: (613) 966-8058, Cell: (613) 391-2097,

Organization Profile

Telesta Therapeutics Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890